To reauthorize the Kay Hagan Tick Act, and for other purposes.
Summary
HR4348 reauthorizes existing tick-borne disease surveillance and response programs through 2030 with strong bipartisan support, but authorizes no new funding amounts. Market impact is negligible as the bill maintains current policy without creating new spending or procurement requirements.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR4348 reauthorizes tick-borne disease programs with no new funding, limiting market impact.
- 2.Bill has strong bipartisan momentum (48-0 committee vote) and a Senate companion, but only extends existing authorities.
- 3.No specific companies are directly affected; the bill funds public health surveillance and response infrastructure.
Market Implications
The bill does not create new revenue streams for public companies. Vector-borne disease diagnostics or vaccine developers (e.g., $PFE, $TAK) are not directly impacted because the bill funds government coordination and health department capacity, not product procurement. Investors should look to standalone appropriations bills for funding levels.
Full Analysis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Veterans SPORT Act
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Protecting Health Care and Lowering Costs Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.